Gantenerumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Gantenerumab
Monoclonal antibody
Type Whole antibody
Source Human
Target Beta-amyloid (Aβ40/42)
Clinical data
Legal status
  • Investigational
Identifiers
CAS Number 89957-37-9 N
ATC code none
UNII 4DF060P933 YesY
KEGG D09680 YesY
Chemical data
Formula C6496H10072N1740O2024S42
Molecular mass 146.3 kg/mol (peptide)
 NYesY (what is this?)  (verify)

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]

Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. [4]

One clinical study was stopped on December 19, 2014 after disappointing results.[5]

As of late 2014, Phase III clinical trials are ongoing.[6]

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
  2. ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  3. ↑ Clinical trial number NCT00531804 for "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease" at ClinicalTrials.gov
  4. ↑ http://www.scarletroadstudy.com/en-CA/index.aspx
  5. ↑ http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Gantenerumab&oldid=702346497"